TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06712069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimodal Intraoperative Neurophysiologic Monitoring (MIONM)
Description: Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) is a real-time, device-based intervention used during neurosurgical procedures to monitor and preserve the integrity of neural pathways. It combines the following modalities:~Somatosensory Evoked Potentials (SSEP): Monitors sensory pathways by stimulating peripheral nerves and recording cortical responses.~Motor Evoked Potentials (MEP): Assesses motor pathways via transcranial stimulation and muscle response evaluation.~Electromyography (EMG): Detects nerve irritation and monitors muscle activity during surgery.~This intervention provides critical real-time feedback to the surgical team, enabling immediate adjustments to prevent neurological damage and enhance surgical outcomes. The Cascade IOMAX system is the primary device used in this study for implementing MIONM.
Study: NCT06706869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Solution
Study: NCT06711614

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Diet
Description: Designed to increase Omega-3 Fatty Acids (Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA)), fruit, and vegetable intake, participants will receive grocery and meal deliveries for approximately 4-weeks via online ordering with dietician counselling.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Diet
Description: Designed to increase Omega-3 Fatty Acids (Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA)), fruit, and vegetable intake, participants will receive grocery and meal deliveries for approximately 4-weeks via online ordering with dietician counselling.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Diet
Description: Participants will receive weekly food subsidies for their groceries for 4-weeks (\~equivalent to the subsidies to provide groceries in the Intervention arm) but are free to purchase whatever they wish. The participants will continue to have dietician counseling during this time.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Diet
Description: Participants will receive weekly food subsidies for their groceries for 4-weeks (\~equivalent to the subsidies to provide groceries in the Intervention arm) but are free to purchase whatever they wish. The participants will continue to have dietician counseling during this time.
Study: NCT06717126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roginolisib
Description: rognolisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roginolisib
Description: rognolisib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator choice of standard therapy
Description: Investigator will choose the most appropriate treatment standardly given to patients
Study: NCT06726148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECI830
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECI830
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECI830
Description: Experimental
Study: NCT05358548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Is a chemotherapy drug. Used to treat kinds of cancer, as determined by the doctor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: It is a type of immunotherapy and works by helping your immune system to kill cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: It is a type of immunotherapy and works by helping your immune system to kill cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: It is a type of immunotherapy and works by helping your immune system to kill cancer cells
Study: NCT06726148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECI830
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECI830
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Approved medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Approved medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Approved medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Approved medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Approved medication
Study: NCT05347810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of repetitive forces mimicking exoskeleton use
Description: The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
Study: NCT06726148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Approved medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Approved medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Approved medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Approved medication
Study: NCT06719661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Uncontrolled type 2 diabetic patients receive dapagliflozin 10 mg tablet once daily. They are asked to take it for 3 months, then return for their final assessment after 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist-led Intervention
Description: Patients with uncontrolled type 2 diabetes will undergo dosage intensification of their dual or triple oral hypoglycemic medicines up to maximum daily doses. Further, they will be advised on specific dietary modification, education on the importance of adherence, strategies to improve adherence, including giving pill boxes, and regular follow-up every month via telephone-based communication.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy group
Description: Patients are receiving their standard dual or triple oral hypoglycemic therapy only.
Study: NCT06731413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Dose of Chemotherapy and Immunotherapy
Description: Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
Study: NCT06731647

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pleurodesis procedures
Description: All pleurodesis procedures will be conducted with a general anesthesia. The choice of hypnotic, analgesic and neuromuscular drugs will be at the discretion of the physician. Selective orotracheal intubation will be done for all patients with a double lumen tube or a blocker according to centers habits. Regional anesthesia (serratus block, paravertebral block and erector spinae block) will be allowed and chosen at the discretion of the physician. Multimodal pain management will be allowed with the use dexamethasone, ketamine and antinociceptive drugs (nefopam, tramadol, paracetamol at the discretion of the physician. After the surgical procedure, the pleural production of liquid or air will be monitored with a chest tube connected to pleural drainage device according to centers habits. Pain will be monitored with during the hospital stay every 12 h using the pain rate scale graded from 0 to 10. Neuropathic pain will be screened at 48h, 1 months, 6 months and 1 year after the inclusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurodesis procedures
Description: All pleurodesis procedures will be conducted with a general anesthesia. The choice of hypnotic, analgesic and neuromuscular drugs will be at the discretion of the physician. Selective orotracheal intubation will be done for all patients with a double lumen tube or a blocker according to centers habits. Regional anesthesia (serratus block, paravertebral block and erector spinae block) will be allowed and chosen at the discretion of the physician. Multimodal pain management will be allowed with the use dexamethasone, ketamine and antinociceptive drugs (nefopam, tramadol, paracetamol at the discretion of the physician. After the surgical procedure, the pleural production of liquid or air will be monitored with a chest tube connected to pleural drainage device according to centers habits. Pain will be monitored with during the hospital stay every 12 h using the pain rate scale graded from 0 to 10. Neuropathic pain will be screened at 48h, 1 months, 6 months and 1 year after the inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KETOPROFEN(RP19583)
Description: one intravenous dose of ketoprofen 100 mg followed by 5 doses every 12 h of ketoprofen LP 100 mg (a total regimen of 6 doses of ketoprofen every 12 h for 72h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo of ketoprofen with the schema of administration consisting in the administration of one intravenous dose of 100 ml of NaCl 0.9% following 6 oral intakes of a placebo pill every 12h (a total regimen of 6 doses of placebo of NSAID every 12 h for 72h)
Study: NCT06731868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet 5 mg
Description: LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet 10 mg
Description: LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPM3770164 sustained release tablet 20 mg
Description: LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LPM3770164 sustained release tablet simulant
Description: LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
Study: NCT06730633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Matters
Description: Heart Matters is a lifestyle modification intervention guided by the theory of planned behavior. Designed to mitigate cardiovascular disease risk factors, the program strives to help participants consume nutritious foods, engage in a more active lifestyle, lose weight and lower their systolic or diastolic blood pressure. Lifestyle modifications can include weight loss, a reduction in percent calorie fat consumption and total sodium intake, improving diet and increasing physical activity, and reducing daily alcoholic beverage consumption.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart Matters
Description: Heart Matters is a lifestyle modification intervention guided by the theory of planned behavior. Designed to mitigate cardiovascular disease risk factors, the program strives to help participants consume nutritious foods, engage in a more active lifestyle, lose weight and lower their systolic or diastolic blood pressure. Lifestyle modifications can include weight loss, a reduction in percent calorie fat consumption and total sodium intake, improving diet and increasing physical activity, and reducing daily alcoholic beverage consumption.
Study: NCT06716151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HB0034 matching placebo
Description: HB0034 matching Palcebo
Study: NCT06729385

Intervention type: DIAGNOSTIC_TEST
Intervention: The blood Proteome Profiling
Description: Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.
Study: NCT06255080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training intervention
Description: The intervention consists of making the intervention group practice till proficiency using the 2019-version.~The control group practices till they have reached proficiency using the standard 2016-version.~We wanted to compare time to completetion for the intervention. For the follow-up test we invited all participants to return after 4-6 weeks (where no training was allowed) and made them practice till proficiency again using the standard 2016-version. Time to reach proficiency for the follow-up test was compared.
Study: NCT06734975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)
Description: Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Superior laryngeal nerve block - Placebo (saline)
Description: Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
Study: NCT06733649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: substance abuse treatment education
Description: Perinatal women and the women's community support will receive a 50 minute education session that provides correct information on opioid agonist medications and neonatal abstinence syndrome.
Study: NCT06733298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ 14C]-labeled RO7269162
Description: Participants will receive one oral dose of \[14C\]-labeled RO7269162.
Study: NCT06733012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splanchnic nerve block
Description: Catheter based ablation on the right greater splanchnic nerve

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-control procedure
Description: Sham-control ablation procedure
Study: NCT06731998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia
Description: For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia
Description: For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Transversus Abdominis Plane block
Description: Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Transversus Abdominis Plane block
Description: Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.
Study: NCT06737731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1681
Description: SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
Study: NCT06739291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIGX1094R
Description: Single drug treatment by SIGX1094R, orally administered once daily.
Study: NCT06740331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of social cognition, memory functioning, and executive functioning processes
Description: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of social cognition, memory functioning, and executive functioning processes
Description: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of social cognition, memory functioning, and executive functioning processes
Description: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of social cognition, memory functioning, and executive functioning processes
Description: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of social cognition, memory functioning, and executive functioning processes
Description: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Analysis of social cognition, memory functioning, and executive functioning processes
Description: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Study: NCT06735378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Cycling
Description: The impact of interdialytic exercise on cardio protection during HD has never been studied. This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intradialytic Cycling
Description: The impact of interdialytic exercise on cardio protection during HD has never been studied. This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
Study: NCT06743308

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Other Best Practice best practice, standard of care, standard of care, standard of care, standard therapy Undergo standard of care oncology follow-up visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Other Best Practice best practice, standard of care, standard of care, standard of care, standard therapy Undergo standard of care oncology follow-up visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06745284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: Survodutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide
Study: NCT06744413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program
Description: A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of these three domains will be utilized to maximize their synergistic anabolic effect.~The duration of the program will be set at 4 weeks.